2,838 research outputs found
Chapter 3. Effectiveness of nature protection legislation in the European Union and the United States:the Habitats Directive and the Endangered Species Act
High-precision Studies of the He(e,ep) Reaction at the Quasielastic Peak
Precision studies of the reaction He(e,ep) using the
three-spectrometer facility at the Mainz microtron MAMI are presented. All data
are for quasielastic kinematics at MeV/c. Absolute cross
sections were measured at three electron kinematics. For the measured missing
momenta range from 10 to 165 MeV/c, no strength is observed for missing
energies higher than 20 MeV. Distorted momentum distributions were extracted
for the two-body breakup and the continuum. The longitudinal and transverse
behavior was studied by measuring the cross section for three photon
polarizations. The longitudinal and transverse nature of the cross sections is
well described by a currently accepted and widely used prescription of the
off-shell electron-nucleon cross-section. The results are compared to modern
three-body calculations and to previous data.Comment: 4 pages, 3 figures. Submitted for publication in Phys. Rev. Let
Measurement of the 12C(e,e'p)11B Two-Body Breakup Reaction at High Missing Momentum Values
The five-fold differential cross section for the 12C(e,e'p)11B reaction was
determined over a missing momentum range of 200-400 MeV/c, in a kinematics
regime with Bjorken x > 1 and Q2 = 2.0 (GeV/c)2. A comparison of the results
and theoretical models and previous lower missing momentum data is shown. The
theoretical calculations agree well with the data up to a missing momentum
value of 325 MeV/c and then diverge for larger missing momenta. The extracted
distorted momentum distribution is shown to be consistent with previous data
and extends the range of available data up to 400 MeV/c.Comment: 12 pages, 1 table and 3 figures for submission to Journal Physics
Pharmacokinetics of acute tryptophan depletion using a gelatin-based protein in male and female Wistar rats
The essential amino acid tryptophan is the precursor of the neurotransmitter serotonin. By depleting the body of tryptophan, brain tryptophan and serotonin levels are temporarily reduced. In this paper, several experiments are described in which dose and treatment effects of acute tryptophan depletion (ATD) using a gelatin-based proteinâcarbohydrate mixture were studied in male and female Wistar rats. Two or three doses of tryptophan depleting mixture resulted in 65â70% depletion after 2â4Â h in males. ATD effects were similar in females, although females may return to baseline levels faster. Treatment effects after four consecutive days of ATD were similar to the effects of 1Â day of treatment. Object recognition memory was impaired 2, 4, and 6Â h after the first of two doses of ATD, suggesting that the central effects occurred rapidly and continued at least 6Â h, in spite of decreasing treatment effects on plasma tryptophan levels at that time point. The method of acute tryptophan depletion described here can be used to study the relationship between serotonin and behaviour in both male and female rats
Investigation of the Exclusive 3He(e,e'pp)n Reaction
Cross sections for the 3He(e,e'pp)n reaction were measured over a wide range
of energy and three- momentum transfer. At a momentum transfer q=375 MeV/c,
data were taken at transferred energies omega ranging from 170 to 290 MeV. At
omega=220 MeV, measurements were performed at three q values (305, 375, and 445
MeV/c). The results are presented as a function of the neutron momentum in the
final-state, as a function of the energy and momentum transfer, and as a
function of the relative momentum of the two-proton system. The data at neutron
momenta below 100 MeV/c, obtained for two values of the momentum transfer at
omega=220 MeV, are well described by the results of continuum-Faddeev
calculations. These calculations indicate that the cross section in this domain
is dominated by direct two-proton emission induced by a one-body hadronic
current. Cross section distributions determined as a function of the relative
momentum of the two protons are fairly well reproduced by continuum-Faddeev
calculations based on various realistic nucleon-nucleon potential models. At
higher neutron momentum and at higher energy transfer, deviations between data
and calculations are observed that may be due to contributions of isobar
currents.Comment: 14 pages, 1 table, 17 figure
One-year safety and efficacy of mitapivat in sickle cell disease:follow-up results of a phase 2, open-label study
Targeting the primary pathogenic event of sickle cell disease (SCD), the polymerization of sickle hemoglobin (HbS), may prevent downstream clinical events. Mitapivat, an oral pyruvate kinase (PK) activator, has therapeutic potential by increasing adenosine triphosphate (ATP) and decreasing 2,3-diphosphoglycerate (2,3-DPG), a glycolytic red blood cell (RBC) intermediate. In the previously reported 8-week dose-finding period of this phase 2, investigator-initiated, open-label study, mitapivat was well tolerated and showed efficacy in SCD. Here, the 1-year fixed-dose extension period is reported in which 9 of 10 included patients (90%) aged â„16 years with SCD (HbSS, HbS/ÎČ0, or HbS/ÎČ+) continued with mitapivat. Mostly mild treatment-emergent adverse events (AEs) (most commonly, transaminase increase and headache) were still reported. Apart from the reported nontreatment-related serious AE (SAE) of a urinary tract infection in the dose-finding period, 1 nontreatment-related SAE occurred in the fixed-dose extension period in a patient who died of massive pulmonary embolism due to COVID-19. Importantly, sustained improvement in Hb level (mean increase, 1.1 ± 0.7 g/dL; P = .0014) was seen, which was accompanied by decreases in markers of hemolysis. In addition, the annualized rate of vaso-occlusive events reduced significantly from a historic baseline of 1.33 ± 1.32 to 0.64 ± 0.87 (P = .0489) when combining the dose-finding period and fixed-dose extension period. Cellularly, the ATP:2,3-DPG ratio and Hb-oxygen affinity significantly increased and RBC sickling (point of sickling) nonsignificantly reduced. Overall, this study demonstrated 1-year safety and efficacy of treatment with mitapivat in SCD, supporting further evaluation in ongoing phase 2/3 study (RISE UP, NCT05031780). This trial was registered at https://www.clinicaltrialsregister.eu/as NL8517 and EudraCT 2019-003438-18.</p
- âŠ